<DOC>
	<DOCNO>NCT01301716</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib dose-escalation study ass safety , tolerability , pharmacokinetics GDC-0980 administer either paclitaxel carboplatin ( without bevacizumab ) pemetrexed cisplatin patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>A Study Safety Pharmacology GDC-0980 Combination With Either Paclitaxel Carboplatin ( With Without Bevacizumab ) Pemetrexed Cisplatin Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically document , incurable , locally advanced , metastatic solid malignancy Adequate hematologic end organ function For female patient childbearing potential male patient partner childbearing potential , agreement use effective form contraception continue use duration study Measurable disease per RECIST ( Response Evaluable Criteria Solid Tumors ) , exception prostate cancer ( two rise PSA Levels meet criterion progression per PSA Working Group ) ovarian cancer ( two rise CA125 level great ULN ) Current dyspnea rest due complication advance malignancy , condition require continuous supplemental oxygen Uncontrolled hypomagnesemia hypokalemia History Grade &gt; = 3 fast hyperglycemia Any condition require fulldose anticoagulant Known HIV infection Known untreated active central nervous system ( CNS ) metastases Pregnancy , lactation , breastfeed Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior first dose study treatment anticipation need major surgical procedure course study For Arm B : Conditions preclude use bevacizumab For Arm C : Conditions preclude use pemetrexed cisplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>